Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tenocytes
- Development stage
- Phase 3
- Lead developer
- Orthocell
- Modality
- Cell Therapies
- Administration
- Intralesional
01
Overview
Autologous tenocytes (specifically the product Ortho-ATI) is a regenerative cell therapy developed by Orthocell Limited for the treatment of chronic degenerate tendons and ligaments. The therapeutic process involves harvesting a small biopsy of healthy tendon tissue from the patient, which is then processed in a specialized laboratory to isolate and expand the tenocytes (tendon cells). These expanded cells are subsequently re-injected into the site of the patient's tendon injury under ultrasound guidance. The therapy is designed to address the underlying pathology of tendinopathy by stimulating the production of high-quality Type I collagen and restoring the structural integrity of the tendon matrix. Ortho-ATI is commercial-stage in Australia and New Zealand, where it is used for indications such as lateral epicondylitis (tennis elbow) and Achilles tendinopathy, and has been evaluated in clinical collaborations for rotator cuff injuries.
- Brand names
- Ortho-ATI
- Other names
- Autologous Tenocyte Implantationautologous tenocyte therapyATT
02
Targets
DDR2 (Discoidin domain receptor tyrosine kinase 2)ITGA2/ITGB1 (Integrin alpha-2/beta-1 receptor)
Beyond the preview
Go deeper on autologous tenocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tenocytes.